Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy

Metabolomics

Volumn 13, Issue 1, 2017, Pages

  Kantae, Vasudev ^a   Krekels, Elke H J ^a   Esdonk, Michiel J Van ^a   Lindenburg, Peter ^a   Harms, Amy C ^a   Knibbe, Catherijne A J ^a   Van der Graaf, Piet H ^a,b   Hankemeier, Thomas ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Biomarker; Metabolomics; Personalized medicine; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pharmacometabolomics

Indexed keywords

BIOLOGICAL MARKER; DRUG METABOLITE;

ARTICLE; CLINICAL PRACTICE; DISCRIMINANT ANALYSIS; DRUG EXPOSURE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; METABOLIC REGULATION; METABOLOMICS; MOLECULAR PATHOLOGY; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRINCIPAL COMPONENT ANALYSIS;

EID: 85006516110     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1143-1     Document Type: Article

References (65)

1. Adourian, A., Jennings, E., Balasubramanian, R., Hines, W. M., Damian, D., Plasterer, T. N., et al. (2008). Correlation network analysis for data integration and biomarker selection. Molecular Biosystems, 4, 249–259.
2. Alomar, M. J. (2014). Factors affecting the development of adverse drug reactions (Review article). Saudi Pharmaceutical Journal, 22(2), 83–94.
3. Backshall, A., Sharma, R., Clarke, S. J., & Keun, H. C. (2011). Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clinical Cancer Research, 17(9), 3019–3028.
4. Bartel, J., Krumsiek, J., & Theis, F. J. (2013). Statistical methods for the analysis of high-throughput metabolomics data. Computational and Structural Biotechnology Journal, 4, e201301009.
5. Bernini, P., Bertini, I., Luchinat, C., Nepi, S., Saccenti, E., Schäfer, H., et al. (2009). Individual human phenotypes in metabolic space and time. Journal of Proteome Research, 8(9), 4264–4271.
6. Carr, D. F., Alfirevic, A., & Pirmohamed, M. (2014). Pharmacogenomics: Current state-of-the-art. Genes, 5(2), 430–443.
7. Chen, C., Gonzalez, F. J., & Idle, J. R. (2007). LC-MS-based metabolomics in drug metabolism. Drug Metabolism Reviews, 39(2–3), 581–597.
8. Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., & Nicholson, J. K. (2009). Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proceedings of the National Academy of Sciences of the United States of America, 106(34), 14728–14733.
9. Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature, 440(7087), 1073–1077.
10. Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., et al. (2011). 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. The International Journal of Neuropsychopharmacology, 14(6), 756–767.
11. Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462(7274), 739–744.
12. Danhof, M., Alvan, G., Dahl, S. G., Kuhlmann, J., & Paintaud, G. (2005). Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharmaceutical Research, 22(9), 1432–1437.
13. Dona, A. C., Jiménez, B., Schäfer, H., Humpfer, E., Spraul, M., Lewis, M. R., et al. (2014). Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Analytical Chemistry, 86(19), 9887–9894.
14. Ellero-Simatos, S., Lewis, J. P., Georgiades, A., Yerges-Armstrong, L. M., Beitelshees, A. L., Horenstein, R. B., et al. (2014). Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT: Pharmacometrics & Systems Pharmacology, 3, e125.
15. Emwas, A.-H. M., Salek, R. M., Griffin, J. L., & Merzaban, J. (2013). NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics, 9(5), 1048–1072.
16. Evans, W. E., & McLeod, H. L. (2003). Pharmacogenomics–drug disposition, drug targets, and side effects. The New England Journal of Medicine, 348(6), 538–549.
17. Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. Nature, 429(6990), 464–468.
18. Fernie, A. R., Trethewey, R. N., Krotzky, A. J., & Willmitzer, L. (2004). Metabolite profiling: From diagnostics to systems biology. Nature Reviews Molecular Cell Biology, 5(9), 763–769.
19. Gabrielsson, J., Fjellström, O., Ulander, J., Rowley, M., & Van Der Graaf, P. H. (2011). Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Current Topics in Medicinal Chemistry, 11(4), 404–418.
20. Garcia, A., & Barbas, C. (2011). Gas chromatography–mass spectrometry (GC–MS)-based metabolomics. Methods in Molecular Biology, 708, 191–204.
21. Guo, L., Milburn, M. V., Ryals, J. A., Lonergan, S. C., Mitchell, M. W., Wulff, J. E., et al. (2015). Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proceedings of the National Academy of Sciences of the United States of America, 112(35), E4901–E4910.
22. Huang, Q., Aa, J., Jia, H., Xin, X., Tao, C., Liu, L., et al. (2015). A Pharmacometabonomic approach to predicting metabolic phenotypes and pharmacokinetic parameters of atorvastatin in healthy volunteers. Journal of Proteome Research, 4(9), 3970–3981.
23. Joerger, M. (2012). Covariate pharmacokinetic model building in oncology and its potential clinical relevance. The AAPS journal, 14(1), 119–132.
24. Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., et al. (2010). Lipidomic analysis of variation in response to simvastatin in the cholesterol and pharmacogenetics study. Metabolomics, 6(2), 191–201.
25. Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., et al. (2011). Enteric microbiome metabolites correlate with response to simvastatin treatment. PloS One, 6(10), e25482.
26. Kaddurah-Daouk, R., Bogdanov, M. B., Wikoff, W. R., Zhu, H., Boyle, S. H., Churchill, E., et al. (2013). Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Translational Psychiatry, 3, e223.
27. Kaddurah-Daouk, R., Boyle, S. H., Matson, W., Sharma, S., Matson, S., Zhu, H., et al. (2011). Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: A proof of concept. Translational Psychiatry, 1, e26.
28. Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008). Metabolomics: A global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology, 48, 653–683.
29. Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry, 12(10), 934–945.
30. Kaddurah-Daouk, R., & Weinshilboum, R. (2015). Metabolomic signatures for drug response phenotypes: Pharmacometabolomics enables precision medicine. Clinical Pharmacology and Therapeutics, 98(1), 71–75.
31. Kaddurah-Daouk, R., & Weinshilboum, R. M. (2014). Pharmacometabolomics: Implications for clinical pharmacology and systems pharmacology. Clinical Pharmacology and Therapeutics, 95(2), 154–167.
32. Kaddurah-Daouk, R., Zhu, H., Sharma, S., Bogdanov, M., Rozen, S. G., Matson, W., et al. (2013). Alterations in metabolic pathways and networks in Alzheimer’s disease. Translational Psychiatry, 3, e244.
33. Kerb, R. (2006). Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters, 234(1), 4–33.
34. Keun, H. C., Sidhu, J., Pchejetski, D., Lewis, J. S., Marconell, H., Patterson, M., et al. (2009). Serum molecular signatures of weight change during early breast cancer chemotherapy. Clinical Cancer Research, 15(21), 6716–6723.
35. Kienana, M., Benz-de Bretagne, I., Nadal-Desbarats, L., Blasco, H., Gyan, E., Choquet, S., et al. (2016). Endogenous metabolites that are substrates of organic anion transporter’s (OATs) predict methotrexate clearance. Pharmacological Research, 6618(16), 30469–30468.
36. Kinross, J. M., Holmes, E., Darzi, A. W., & Nicholson, J. K. (2011). Metabolic phenotyping for monitoring surgical patients. Lancet (London, England), 377(9780), 1817–1819.
37. Kitsios, G. D., & Kent, D. M. (2012). Personalised medicine: Not just in our genes. BMJ (Clinical Research Ed.), 344, e2161.
38. Konig, J., Muller, F., & Fromm, M. F. (2013). Transporters and drug-drug interactions: Important determinants of drug disposition and effects. Pharmacological Reviews, 65(3), 944–966.
39. Kotze, H. L., Armitage, E. G., Sharkey, K. J., Allwood, J. W., Dunn, W. B., Williams, K. J., & Goodacre, R. (2013). A novel untargeted metabolomics correlation-based network analysis incorporating human metabolic reconstructions. BMC Systems Biology, 7(1), 107.
40. Krauss, R. M., Zhu, H., & Kaddurah-Daouk, R. (2013). Pharmacometabolomics of statin response. Clinical Pharmacology and Therapeutics, 94(5), 562–565.
41. Levy, G. (1998). Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clinical Pharmacokinetics, 34(4), 323–333.
42. Li, H., & Jia, W. (2013). Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clinical Pharmacology and Therapeutics, 94(5), 574–581.
43. Lindon, J. C., Holmes, E., & Nicholson, J. K. (2006). Metabonomics techniques and applications to pharmaceutical research & development. Pharmaceutical Research, 23(6), 1075–1088.
44. Nicholson, J. K., Everett, J. R., & Lindon, J. C. (2012). Longitudinal pharmacometabonomics for predicting patient responses to therapy: Drug metabolism, toxicity and efficacy. Expert Opinion on Drug Metabolism & Toxicology, 8(2), 135–139.
45. Nicholson, J. K., Wilson, I. D., & Lindon, J. C. (2011). Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics, 12(1), 103–111.
46. Phapale, P. B., Kim, S.-D., Lee, H. W., Lim, M., Kale, D. D., Kim, Y.-L., et al. (2010). An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clinical Pharmacology and Therapeutics, 87(4), 426–436.
47. Pirmohamed, M. (2014). Personalized pharmacogenomics: Predicting efficacy and adverse drug reactions. Annual Review of Genomics and Human Genetics, 15, 349–370.
48. Quinones, M. P., & Kaddurah-Daouk, R. (2009). Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiology of Disease, 35(2), 165–176.
49. Rahmioglu, N., Le Gall, G., Heaton, J., Kay, K. L., Smith, N. W., Colquhoun, I. J., et al. (2011). Prediction of variability in CYP3A4 induction using a combined 1 H NMR metabonomics and targeted UPLC-MS approach. Journal of Proteome Research, 10(6), 2807–2816.
50. Schnackenberg, L. K. (2007). Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century. Expert Review of Molecular Diagnostics, 7(3), 247–259.
51. Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520(7549), 609–611.
52. Sharma, A., Pilote, S., Bélanger, P. M., Arsenault, M., & Hamelin, B. A. (2004). A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: A pilot study. British Journal of Clinical Pharmacology, 58(3), 288–297.
53. Shin, K.-H., Choi, M. H., Lim, K. S., Yu, K.-S., Jang, I.-J., & Cho, J.-Y. (2013). Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clinical Pharmacology and Therapeutics, 94(5), 601–609.
54. Suhre, K., Shin, S.-Y., Petersen, A.-K., Mohney, R. P., Meredith, D., Wägele, B., et al. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature, 477, 54–60.
55. Tay-Sontheimer, J., Shireman, L. M., Beyer, R. P., Senn, T., Witten, D., Pearce, R. E., et al. (2014). Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics, 15(16), 1947–1962.
56. Trupp, M., Zhu, H., Wikoff, W. R., Baillie, R. A., Zeng, Z.-B., Karp, P. D., et al. (2012). Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PloS One, 7(7), e38386.
57. van der Greef, J., Hankemeier, T., & McBurney, R. N. (2006). Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics, 7(7), 1087–1094.
58. van der Greef, J., & McBurney, R. N. (2005). Rescuing drug discovery: In vivo systems pathology and systems pharmacology. Nature Reviews Drug Discovery, 4(12), 961–967.
59. Vicini, P., & van der Graaf, P. H. (2013). Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clinical Pharmacology and Therapeutics, 93(5), 379–381.
60. Weinshilboum, R. (2003). Inheritance and drug response. The New England Journal of Medicine, 348(6), 529–537.
61. Wright, D. F. B., Winter, H. R., & Duffull, S. B. (2011). Understanding the time course of pharmacological effect: a PKPD approach. British Journal of Clinical Pharmacology, 71(6), 815–823.
62. Yao, J. K., Dougherty, G. G., Reddy, R. D., Keshavan, M. S., Montrose, D. M., Matson, W. R., et al. (2010). Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Molecular Psychiatry, 15(9), 938–953.
63. Yerges-Armstrong, L. M., Ellero-Simatos, S., Georgiades, A., Zhu, H., Lewis, J. P., Horenstein, R. B., et al. (2013). Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics, 94(4), 525–532.
64. Zhao, Y.-Y., Chen, H., Tian, T., Chen, D.-Q., Bai, X., & Wei, F. (2014). A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS. PloS One, 9(12), e115467.
65. Zhu, H., Bogdanov, M. B., Boyle, S. H., Matson, W., Sharma, S., Matson, S., et al. (2013). Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder-possible role for methoxyindole pathway. PloS One, 8(7), e68283.